OXALIPLATIN

LOE Approaching

oxaliplatin

NDAINTRAVENOUSINJECTABLE
Approved
Aug 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent…

Pharmacologic Class:

Platinum-based Drug

Indications (1)

Clinical Trials (5)

NCT07490301Phase 2/3Not Yet Recruiting

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Started Jun 2026
900 enrolled
Metastatic Pancreatic Ductal AdenocarcinomaPDAC
NCT07281768Phase 2Not Yet Recruiting

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Started Apr 2026
66 enrolled
Colorectal Cancer
NCT06624085Phase 1Recruiting

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Started Apr 2025
50 enrolled
Lymphoma
NCT06820463Phase 2Recruiting

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Started Apr 2025
390 enrolled
Metastatic Colorectal Cancer
NCT06806033Phase 2Recruiting

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Started Mar 2025
100 enrolled
B-Cell Non-Hodgkins Lymphoma